These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15735447)

  • 1. Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
    van Leth F; Huisamen CB; Badaro R; Vandercam B; de Wet J; Montaner JS; Hall DB; Wit FW; Lange JM;
    J Acquir Immune Defic Syndr; 2005 Mar; 38(3):296-300. PubMed ID: 15735447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
    Leth FV; Kappelhoff BS; Johnson D; Losso MH; Boron-Kaczmarska A; Saag MS; Livrozet JM; Hall DB; Leith J; Huitema AD; Wit FW; Beijnen JH; Lange JM;
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):232-9. PubMed ID: 16545009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
    van Leth F; Andrews S; Grinsztejn B; Wilkins E; Lazanas MK; Lange JM; Montaner J;
    AIDS; 2005 Mar; 19(5):463-71. PubMed ID: 15764851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
    van Leth F; Conway B; Laplumé H; Martin D; Fisher M; Jelaska A; Wit FW; Lange JM;
    Antivir Ther; 2004 Oct; 9(5):721-8. PubMed ID: 15535409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
    Keiser P; Nassar N; White C; Koen G; Moreno S
    HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals.
    Núñez M; Soriano V; Martín-Carbonero L; Barrios A; Barreiro P; Blanco F; García-Benayas T; González-Lahoz J
    HIV Clin Trials; 2002; 3(3):186-94. PubMed ID: 12032877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
    HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
    Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM
    BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
    Kamya MR; Mayanja-Kizza H; Kambugu A; Bakeera-Kitaka S; Semitala F; Mwebaze-Songa P; Castelnuovo B; Schaefer P; Spacek LA; Gasasira AF; Katabira E; Colebunders R; Quinn TC; Ronald A; Thomas DL; Kekitiinwa A;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):187-93. PubMed ID: 17693883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
    Siegfried NL; Van Deventer PJ; Mahomed FA; Rutherford GW
    Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD004535. PubMed ID: 16625606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.
    Manosuthi W; Tantanathip P; Prasithisirikul W; Likanonsakul S; Sungkanuparph S
    BMC Infect Dis; 2008 Oct; 8():136. PubMed ID: 18851761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz.
    Re MC; Monari P; Bon I; Borderi M; Gibellini D; Schiavone P; Vitone F; Furlini G; La Placa M
    Int J Antimicrob Agents; 2002 Sep; 20(3):223-6. PubMed ID: 12385703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection.
    Yogev R; Lee S; Wiznia A; Nachman S; Stanley K; Pelton S; Mofenson L; Fiscus S; Jimenez E; Rathore MH; Smith ME; Song LY; McIntosh K;
    Pediatr Infect Dis J; 2002 Feb; 21(2):119-25. PubMed ID: 11840078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081).
    Morand-Joubert L; Marcellin F; Launay O; Guiramand-Hugon S; Gérard L; Yeni P; Aboulker JP;
    J Acquir Immune Defic Syndr; 2005 Mar; 38(3):268-76. PubMed ID: 15735443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
    Ochoa de Echagüen A; Arnedo M; Xercavins M; Martinez E; Rosón B; Ribera E; Domingo P; González A; Riera M; Llibre JM; Gatell JM; Dalmau D;
    AIDS; 2005 Sep; 19(13):1385-91. PubMed ID: 16103769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.